Viewing Study NCT03173560

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:09 AM
Ignite Modification Date: 2026-05-08 @ 9:44 AM
Study NCT ID: NCT03173560
Status: COMPLETED
Last Update Posted: 2025-04-01
First Post: 2017-05-22
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Sponsor: Eisai Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Renal Cell Carcinoma View
None lenvatinib View
None everolimus View
None E7080 View
None VEGF-targeted treatment View